Cargando…
Advances in mRNA vaccines
mRNA vaccines have been increasingly recognized as a powerful vaccine platform since the FDA approval of two COVID-19 mRNA vaccines, which demonstrated outstanding prevention efficacy as well as great safety profile. Notably, nucleoside modification and lipid nanoparticle-facilitated delivery has gr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214710/ https://www.ncbi.nlm.nih.gov/pubmed/36064266 http://dx.doi.org/10.1016/bs.ircmb.2022.04.011 |
_version_ | 1784731075559292928 |
---|---|
author | Li, Mengyun Wang, Zining Xie, Chunyuan Xia, Xiaojun |
author_facet | Li, Mengyun Wang, Zining Xie, Chunyuan Xia, Xiaojun |
author_sort | Li, Mengyun |
collection | PubMed |
description | mRNA vaccines have been increasingly recognized as a powerful vaccine platform since the FDA approval of two COVID-19 mRNA vaccines, which demonstrated outstanding prevention efficacy as well as great safety profile. Notably, nucleoside modification and lipid nanoparticle-facilitated delivery has greatly improved the immunogenicity, stability, and translation efficiency of mRNA molecule. Here we review the recent progress in mRNA vaccine development, including nucleoside modification, in vitro synthesis and product purification, and lipid nanoparticle vectors for in vivo delivery and efficient translation. We also briefly introduce the clinical application of mRNA vaccine in preventing infectious diseases and treating inflammatory diseases including cancer. |
format | Online Article Text |
id | pubmed-9214710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92147102022-06-22 Advances in mRNA vaccines Li, Mengyun Wang, Zining Xie, Chunyuan Xia, Xiaojun Int Rev Cell Mol Biol Article mRNA vaccines have been increasingly recognized as a powerful vaccine platform since the FDA approval of two COVID-19 mRNA vaccines, which demonstrated outstanding prevention efficacy as well as great safety profile. Notably, nucleoside modification and lipid nanoparticle-facilitated delivery has greatly improved the immunogenicity, stability, and translation efficiency of mRNA molecule. Here we review the recent progress in mRNA vaccine development, including nucleoside modification, in vitro synthesis and product purification, and lipid nanoparticle vectors for in vivo delivery and efficient translation. We also briefly introduce the clinical application of mRNA vaccine in preventing infectious diseases and treating inflammatory diseases including cancer. Elsevier Inc. 2022 2022-06-21 /pmc/articles/PMC9214710/ /pubmed/36064266 http://dx.doi.org/10.1016/bs.ircmb.2022.04.011 Text en Copyright © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Li, Mengyun Wang, Zining Xie, Chunyuan Xia, Xiaojun Advances in mRNA vaccines |
title | Advances in mRNA vaccines |
title_full | Advances in mRNA vaccines |
title_fullStr | Advances in mRNA vaccines |
title_full_unstemmed | Advances in mRNA vaccines |
title_short | Advances in mRNA vaccines |
title_sort | advances in mrna vaccines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214710/ https://www.ncbi.nlm.nih.gov/pubmed/36064266 http://dx.doi.org/10.1016/bs.ircmb.2022.04.011 |
work_keys_str_mv | AT limengyun advancesinmrnavaccines AT wangzining advancesinmrnavaccines AT xiechunyuan advancesinmrnavaccines AT xiaxiaojun advancesinmrnavaccines |